OSLO, Norway--(BUSINESS WIRE)-- Reference is made to the notice of Extraordinary General Meeting distributed to the shareholders of Nordic Nanovector AS on 19 June 2014.
In accordance with the proposals set out in the notice, the Extraordinary General Meeting has today resolved to issue 10 million new shares in the Private Placement at a price of NOK 25 raising gross proceeds of NOK 250 million. Furthermore, it was resolved to conduct a subsequent share issue of up to 2 million new shares at a price of NOK 25, raising gross proceeds of up to NOK 50 million.
The subsequent share issue will be directed towards the shareholders of the Company as of 27 June 2014 except for (i) shareholders participating in the Private Placement, and (ii) shareholders in jurisdictions other than Norway and where an offer to participate in the share issue is not allowed or would require approval or registration of a prospectus or similar measures.
If not all subscription rights are used by the eligible holders, then the remaining shares may be subscribed to by the shareholders of the Company as of 27 June 2014. The allotment of these remaining shares shall take place on the basis of shareholding as of that date, but so that shares allotted to the shareholder in the Private Placement or pursuant to subscription rights in the subsequent share issue shall be deemed to be allotted shares.
The Company will prepare a prospectus in connection with the subsequent share issue. The subscription period in the subsequent share issue will not commence until the prospectus is approved by the Financial Supervisory Authority of Norway (the “NFSA”) and the prospectus has been published.
The Company expects that the prospectus will be approved by the NFSA in late August 2014. Eligible holders will receive the prospectus and a subscription form by mail when the prospectus has been approved.
The Extraordinary General Meeting also resolved the other matters on the agenda in accordance with the proposals of the Board of Directors, as further set out in the attached minutes of the Extraordinary General Meeting.
ABG Sundal Collier and DNB Markets have acted as managers in the private placement and will act as managers in the subsequent share issue.
About Nordic Nanovector
AS Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other hematological malignancies.
Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).
This announcement is not and does not form a part of any offer for sale of securities.
Copies of this announcement are not being made and may not be distributed or sent into the United States, Australia, Canada, Japan or any other jurisdiction in which such distribution would be unlawful or would require registration or other measures.
The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any part of the offering in the United States or to conduct a public offering of securities in the United States. Any offering of the securities referred to in this announcement will be made by means of a prospectus.
This announcement is not a prospectus for the purposes of Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the “Prospectus Directive”). Investors should not subscribe for any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus. In any EEA Member State other than Norway that has implemented the Prospectus Directive, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State.
This communication is only being distributed to and is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. Persons distributing this communication must satisfy themselves that it is lawful to do so.
The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice.
This information was brought to you by Cision http://news.cision.com
Source: Nordic Nanovector